Latest Diagnostics News

Page 1 of 72
BCAL Diagnostics is prepared to support an expedited Genetic Signatures and Microba merger, but only on revised terms, a GSS board reset and protections for a superior proposal. It may also provide up to $2 million in working capital to Microba, subject to raising the funds itself.
Ada Torres
Ada Torres
19 Nov 2026
Clarity Pharmaceuticals has completed final follow-up assessments for every participant in its registrational Phase III AMPLIFY trial of 64Cu-SAR-bisPSMA. Topline results from AMPLIFY and the related CLARIFY trial are expected in the first half of 2027, with the data intended to support US FDA applications.
Victor Sage
Victor Sage
19 Nov 2026
Genetic Signatures has abandoned its proposed merger with Microba Life Sciences after Microba said it lacked the financial capacity to complete the transaction without fresh capital. GSS also declined to provide unsecured working capital funding, leaving the shareholder vote and Takeovers Panel process to be unwound separately.
Ada Torres
Ada Torres
18 Nov 2026
Genetic Signatures has ended its proposed merger with Microba Life Sciences after Microba said it could not complete the transaction without raising more capital. The decision also removes the deal’s shareholder vote and leaves a Takeovers Panel application awaiting clarification.
Ada Torres
Ada Torres
18 Nov 2026
Revvity has set out a long-range growth strategy built around AI-enabled scientific discovery, recurring software revenue and specialised diagnostics. The plan includes double-digit adjusted EPS growth, margin expansion and about US$5 billion of capital capacity through 2031, but formal 2027 guidance is still pending.
Ada Torres
Ada Torres
14 Nov 2026
BCAL Diagnostics, an 18.46% shareholder of Genetic Signatures, has asked the Takeovers Panel to intervene over the proposed merger with Microba Life Sciences. The application alleges the deal structure and shareholder process lack adequate protections, although no Panel has yet been appointed and no decision has been made.
Ada Torres
Ada Torres
13 Nov 2026
Genetic Signatures’ proposed Microba merger faces a formal challenge from 18.46% shareholder BCAL Diagnostics, which alleges the process lacks adequate protections and information for GSS investors. The Takeovers Panel has not yet appointed a sitting Panel or decided whether to open proceedings.
Ada Torres
Ada Torres
13 Nov 2026
Mach7 Technologies has signed Temple Health to a five-year licence for its eUnity Viewer and Vendor Neutral Archive, with Year 1 annual recurring revenue expected to reach A$0.5 million. The revenue will depend on go-live and first productive use, forecast within six to 12 months.
Victor Sage
Victor Sage
13 Nov 2026
Imricor Medical Systems (ASX:IMR) has moved from regulatory preparation into US commercial deployment, signing its first two NorthStar hospital customers within weeks of launch. The milestone comes with sharply higher quarterly revenue, a fresh Philips pathway and a still-heavy cash burn.
Victor Sage
Victor Sage
13 Nov 2026
ADX Energy has secured a rig for the GOLD-1 shallow gas well in Upper Austria, with mobilisation set for 4 January 2027. The prospect carries a mean prospective resource estimate of 8.3 BCF, but drilling, testing and commercial development risks remain ahead.
Victor Sage
Victor Sage
12 Nov 2026
Cleo Diagnostics has commissioned three Ella immunoassay instruments at a US laboratory as it prepares to begin the final major clinical testing program for its pre-surgical ovarian cancer test. The approximately 1,470-sample program is intended to support a planned FDA 510(k) submission in the first half of calendar 2027, but no clinical results have yet been reported.
Ada Torres
Ada Torres
12 Nov 2026
BD finished fiscal 2026 with higher revenue, adjusted earnings and cash generation, while setting low single-digit growth expectations for the year ahead. Its proposed US$19 billion US investment adds scale to the strategy, but remains tied to milestones and future implementation.
Ada Torres
Ada Torres
5 Nov 2026

Browse the archive

Full archive